VERSA-GC Study: Machine Learning Model to Predict 5-FU Chemotherapy Response in Gastric Cancer — Precision Oncology Advances

References

1. 1.Bass, A. J., Thorsson, V., Shmulevich, I., Reynolds, S. M., Miller, M., Bernard, B., Hinoue, T., Laird, P. W., Curtis, C., Shen, H., Weisenberger, D. J., Schultz, N., Shen, R., Weinhold, N., Kelsen, D. P., Bowlby, R., Chu, A., Kasaian, K., Mungall, A. J., ... Cancer Genome Atlas Research Network. (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513(7517), 202-209. https://doi.org/10.1038/nature13480
2. 2.City of Hope Medical Center. (2024). A Multicenter Observational Study to Develop and Validate an Alternative Splicing-Based Machine Learning Model for Predicting Response to 5-FU-Based Adjuvant Chemotherapy in Gastric Cancer (VERSA-GC Study). ClinicalTrials.gov. NCT07587229. https://clinicaltrials.gov/study/NCT07587229
3. 3.Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., Chua, Y. J., & MAGIC Trial Participants. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11-20. https://doi.org/10.1056/NEJMoa055531
4. 4.Japanese Gastric Cancer Association. (2021). Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer, 24(1), 1-21. https://doi.org/10.1007/s10120-020-01042-y
5. 5.Kahles, A., Lehmann, K. V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T., Stegle, O., Kohlbacher, O., Sander, C., Caesar-Johnson, S. J., Demchok, J. A., Felau, I., Kasapi, M., Ferguson, M. L., Hutter, C. M., Sofia, H. J., Tarnuzzer, R., Wang, Z., Yang, L., ... Rätsch, G. (2018). Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell, 34(2), 211-224.e6. https://doi.org/10.1016/j.ccell.2018.07.001
6. 6.Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., & Martenson, J. A. (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine, 345(10), 725-730. https://doi.org/10.1056/NEJMoa010187
7. 7.Noh, S. H., Park, S. R., Yang, H. K., Chung, H. C., Chung, I. J., Kim, S. W., Kim, H. H., Choi, J. H., Kim, H. K., Yu, W., Lee, J. I., Shin, D. B., Ji, J., Chen, J. S., Lim, Y., Ha, S., Bang, Y. J., & CLASSIC trial investigators. (2014). Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncology, 15(12), 1389-1396. https://doi.org/10.1016/S1470-2045(13)70541-8
8. 8.Seiler, M., Peng, S., Agrawal, A. A., Palacino, J., Teng, T., Zhu, P., Smith, P. G., Caesar-Johnson, S. J., Demchok, J. A., Felau, I., Kasapi, M., Ferguson, M. L., Hutter, C. M., Sofia, H. J., Tarnuzzer, R., Wang, Z., Yang, L., Zenklusen, J. C., Zhang, J., ... Buonamici, S. (2018). Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Reports, 23(1), 282-296.e4. https://doi.org/10.1016/j.celrep.2018.01.088
9. 9.Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020). Gastric cancer. Lancet, 396(10251), 635-648. https://doi.org/10.1016/S0140-6736(20)31288-5
10. 10.Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660